Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial

Mauro Chiarito, Jorge Sanz-Sanchez, Raffaele Piccolo, Francesco Condello, Gaetano Liccardo, Matteo Maurina, Marisa Avvedimento, Damiano Regazzoli, Paolo Pagnotta, Hector M. Garcia-Garcia, Roxana Mehran, Massimo Federici, Gianluigi Condorelli, Jose Luis Diez Gil, Bernhard Reimers, Giuseppe Ferrante, Giulio Stefanini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Despite paucity of data, it is common practice to discontinue metformin before invasive coronary angiography due to an alleged risk of Metformin-Associated Lactic Acidosis (M-ALA). We aimed at assessing the safety of metformin continuation in diabetic patients undergoing coronary angiography in terms of significant increase in lactate levels. Methods: In this open-label, prospective, multicentre, single-arm trial, all diabetic patients undergoing coronary angiography with or without percutaneous coronary intervention at 3 European centers were screened for enrolment. The primary endpoint was the increase in lactate levels from preprocedural levels at 72-h after the procedure. Secondary endpoints included contrast associated-acute kidney injury (CA-AKI), M-ALA, and all-cause mortality. Results: 142 diabetic patients on metformin therapy were included. Median preprocedural lactate level was 1.8 mmol/l [interquartile range (IQR) 1.3–2.3]. Lactate levels at 72 h after coronary angiography were 1.7 mmol/l (IQR 1.3–2.3), with no significant differences as compared to preprocedural levels (p = 0.91; median difference = 0; IQR − 0.5 to 0.4 mmol/l). One patient had 72-h levels ≥ 5 mmol/l (5.3 mmol/l), but no cases of M-ALA were reported. CA-AKI occurred in 9 patients (6.1%) and median serum creatinine and estimated glomerular filtration rate remained similar throughout the periprocedural period. At a median follow-up of 90 days (43–150), no patients required hemodialysis and 2 patients died due to non-cardiac causes. Conclusions: In diabetic patients undergoing invasive coronary angiography, metformin continuation throughout the periprocedural period does not increase lactate levels and was not associated with any decline in renal function. Trial registration: The study was registered at Clinicaltrials.gov (NCT04766008). Graphical Abstract: [Figure not available: see fulltext.].

Original languageEnglish
Article number28
JournalCardiovascular Diabetology
Volume22
Issue number1
DOIs
StatePublished - Dec 2023

Keywords

  • Coronary angiography
  • Metformin
  • Metformin-associated lactic acidosis
  • Percutaneous coronary intervention

Fingerprint

Dive into the research topics of 'Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial'. Together they form a unique fingerprint.

Cite this